Dimensional analysis of depressive, anxious and somatic symptoms presented by primary care patients and their relationship with ICD-11 PHC proposed diagnoses

Ziebold, Carolina; Goldberg, David; Reed, Geoffrey M.; Minhas, Fareed Aslam; Razzaque, Bushra; Fortes, Sandra; Robles, Rebeca; Lam, Tai Pong; Bobes, Julio; Iglesias, Celso; Cogo‐Moreira, Hugo; Garcı́a, J.A.; Mari, Jair J.

doi:10.1017/s0033291718001381

Cited by 18 publications

(12 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The ICD‐11 includes the category of mixed depressive and anxiety disorder because of its importance in primary care settings. This category has been moved from anxiety disorders in the ICD‐10 to depressive disorders in the ICD‐11 because of evidence of its overlap with mood symptomatology.…”

Section: Summary Of Changes By Icd‐11 Disorder Groupingmentioning

confidence: 99%

Innovations and changes in the ICD‐11 classification of mental, behavioural and neurodevelopmental disorders

Reed¹,

First²,

Kogan³

et al. 2019

World Psychiatry

Self Cite

579

343

View full text Add to dashboard Cite

The development of the ICD-11 CDDG over the past decade, based on the principles of clinical utility and global applicability, has been the most broadly international, multilingual, multidisciplinary and participative revision process ever implemented for a classification of mental disorders. Innovations in the ICD-11 include the provision of consistent and systematically characterized information, the adoption of a lifespan approach, and culture-related guidance for each disorder. Dimensional approaches have been incorporated into the classification, particularly for personality disorders and primary psychotic disorders, in ways that are consistent with current evidence, are more compatible with recovery-based approaches, eliminate artificial comorbidity, and more effectively capture changes over time. Here we describe major changes to the structure of the ICD-11 classification of mental disorders as compared to the ICD-10, and the development of two new ICD-11 chapters relevant to mental health practice. We illustrate a set of new categories that have been added to the ICD-11 and present the rationale for their inclusion. Finally, we provide a description of the important changes that have been made in each ICD-11 disorder grouping. This information is intended to be useful for both clinicians and researchers in orienting themselves to the ICD-11 and in preparing for implementation in their own professional contexts.

show abstract

Section: Summary Of Changes By Icd‐11 Disorder Groupingmentioning

confidence: 99%

Innovations and changes in the ICD‐11 classification of mental, behavioural and neurodevelopmental disorders

Reed¹,

First²,

Kogan³

et al. 2019

World Psychiatry

Self Cite

579

343

View full text Add to dashboard Cite

show abstract

“…The new diagnosis in this classification, underlying its impact on patients’ everyday functioning and quality of life, is anxious depression [ 42 ]. Additionally, the ICD-11 includes the category of mixed depressive and anxiety disorder (MDAD) in this section because of its importance in primary care settings and because of evidence confirming its overlap with mood symptomatology [ 71 ]. Therefore, our inclusion criteria may provide the basis for performing a study of the real-life population disabled because of depressive symptoms.…”

Section: Discussionmentioning

confidence: 99%

The Influence of Probiotic Supplementation on Depressive Symptoms, Inflammation, and Oxidative Stress Parameters and Fecal Microbiota in Patients with Depression Depending on Metabolic Syndrome Comorbidity—PRO-DEMET Randomized Study Protocol

Gawlik-Kotelnicka

Skowrońska

Margulska

et al. 2021

JCM

View full text Add to dashboard Cite

There is a huge need to search for new treatment options and potential biomarkers of therapeutic response to antidepressant treatment. Depression and metabolic syndrome often coexist, while a pathophysiological overlap, including microbiota changes, may play a role. The paper presents a study protocol that aims to assess the effect of probiotic supplementation on symptoms of depression, anxiety and stress, metabolic parameters, inflammatory and oxidative stress markers, as well as fecal microbiota in adult patients with depressive disorders depending on the co-occurrence of metabolic syndrome. The trial will be a four-arm, parallel-group, prospective, randomized, double-blind, controlled design that will include 200 participants and will last 20 weeks (ClinicalTrials.gov identifier: NCT04756544). The probiotic preparation will contain Lactobacillus helveticus Rosell®-52, Bifidobacterium longum Rosell®-175. We will assess the level of depression, anxiety and stress, quality of life, blood pressure, body mass index and waist circumference, white blood cells count, serum levels of C-reactive protein, high-density lipoprotein (HDL) cholesterol, triglycerides, fasting glucose, fecal microbiota composition and the level of some fecal microbiota metabolites, as well as serum inflammatory markers and oxidative stress parameters. The proposed trial may establish a safe and easy-to-use adjunctive treatment option in a subpopulation of depressive patients only partially responsive to pharmacologic therapy.

show abstract

“…everyday functioning and quality of life, is anxious depression [35]. Additionally, the ICD-11 includes the category of mixed depressive and anxiety disorder (MDAD) in this section because of its importance in primary care settings and because of evidence confirming its overlap with mood symptomatology [52]. Therefore, our inclusion criteria may provide the basis for performing a study of the real-life population disabled because of depressive symptoms.…”

Section: Discussionmentioning

confidence: 99%

The Influence of Probiotic Supplementation on Depressive Symptoms, Inflammation and Oxidative Stress Parameters and Faecal Microbiota in Patients with Depression Depending on Metabolic Syndrome Comorbidity – PRO-DEMET Randomised Study Protocol

Gawlik-Kotelnicka¹,

Skowrońska²,

Margulska³

et al. 2021

Preprint

View full text Add to dashboard Cite

There is a huge need to search for new treatment options and potential biomarkers of therapeutic response to antidepressant treatment. Depression and metabolic syndrome often coexist while pathophysiological overlap, including microbiota changes, may play a role. The aim of the study is to assess the effect of probiotic supplementation on symptoms of depression, anxiety and stress, metabolic parameters, inflammation and oxidative stress markers, and faecal microbiota in adult patients with depressive disorders depending on the co-occurance of MetS. The trial will be a four-arm, parallel group, prospective, randomized, double-blind, controlled design that will include 200 participants and will last 20 weeks. The probiotic preparation will contain Lactobacillus helveticus Rosell®-52, Bifidobacterium longum Rosell®-175. We will assess the level of depression, anxiety and stress, quality of life, blood pressure, body mass index and waist circumference, white blood cells count, serum levels of C-reactive protein, HDL cholesterol, triglicerides, fasting glucose, faecal microbiota composition and the level of some faecal microbiota metabolites, as well as inflammation markers and oxidative stress parameters in serum. The trial may establish a safe and easy-to-use treatment option as an adjunct in a subpopulation of depressive patients only partially responsive to pharmacologic treatment. (ClinicalTrials.gov identifier: ).

show abstract

Dimensional analysis of depressive, anxious and somatic symptoms presented by primary care patients and their relationship with ICD-11 PHC proposed diagnoses

Cited by 18 publications

References 30 publications

Innovations and changes in the ICD‐11 classification of mental, behavioural and neurodevelopmental disorders

Innovations and changes in the ICD‐11 classification of mental, behavioural and neurodevelopmental disorders

The Influence of Probiotic Supplementation on Depressive Symptoms, Inflammation, and Oxidative Stress Parameters and Fecal Microbiota in Patients with Depression Depending on Metabolic Syndrome Comorbidity—PRO-DEMET Randomized Study Protocol

The Influence of Probiotic Supplementation on Depressive Symptoms, Inflammation and Oxidative Stress Parameters and Faecal Microbiota in Patients with Depression Depending on Metabolic Syndrome Comorbidity – PRO-DEMET Randomised Study Protocol

Contact Info

Product

Resources

About